All Trials

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: For adults with unresectable recurrent/metastatic HNSCC (oral cavity/oropharynx/hypopharynx/larynx) with measurable disease and ECOG 0–2 who have radiographic progression on/after prior immune checkpoint inhibitor therapy and no prior EGFR-targeted therapy or taxane for R/M disease. Treatment is oral NRC-2694-A (investigational EGFR tyrosine kinase inhibitor) 300 mg daily plus paclitaxel 175 mg/m² IV every 21 days (≥6 cycles per protocol).

ClinicalTrials.gov ID: NCT05283226

A Phase 3, Multicenter, Randomized, Open-label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients With Previously Treated Advanced Biliary Tract Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or locally advanced/unresectable biliary tract cancer (intrahepatic/extrahepatic cholangiocarcinoma or gallbladder cancer) and ECOG 0–1 whose disease has progressed after exactly one prior platinum-based systemic regimen for advanced disease (prior matched targeted therapy for actionable alterations and/or PD-1/PD-L1 for MSI-H allowed). Patients are randomized to nanvuranlat, an IV small-molecule LAT1 (SLC7A5) amino acid transporter inhibitor intended to disrupt essential amino acid uptake and downstream mTOR signaling, versus physician’s choice of FOLFOX, FOLFIRI, or best supportive care (with initial dose-regimen selection followed by confirmatory comparison).

ClinicalTrials.gov ID: NCT07265674

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously untreated stage IV metastatic squamous NSCLC (ECOG 0–1; measurable disease; requires non-irradiated metastatic tumor tissue for sequencing; controlled HIV and treated/undetectable HBV/HCV allowed) receive first-line pembrolizumab plus carboplatin and a taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab maintenance. Participants are randomized double-blind to add V940 (mRNA-4157/intismeran autogene), an individualized lipid nanoparticle mRNA neoantigen vaccine encoding up to 34 patient-specific neoantigens to stimulate CD4+/CD8+ T-cell responses, versus placebo.

ClinicalTrials.gov ID: NCT07221474

An Open-Label, Multicenter, Phase 2 Study With Safety Lead-In of Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab in Patients With Angiosarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with locally advanced/unresectable or metastatic, RECIST-measurable cutaneous angiosarcoma with at least one injectable lesion and ECOG 0–1 who have progressed on prior taxane/anthracycline chemotherapy and on an immunotherapy-based regimen within 6 months. Patients receive intratumoral vusolimogene oderparepvec (RP1), an HSV-1–derived oncolytic immunotherapy engineered to express GM-CSF and a fusogenic glycoprotein to enhance immunogenic tumor cell death/antigen presentation, in combination with pembrolizumab (PD-1 blockade).

ClinicalTrials.gov ID: NCT06898970

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults (≥18) with unresectable locally advanced or metastatic alveolar soft part sarcoma (currently enrolling; prior systemic therapy allowed except prior cediranib) receive oral anlotinib (AL3818/catequentinib), a multitarget anti-angiogenic TKI (VEGFR1–3/FGFR1–4/PDGFRα/β/c-Kit), 12 mg daily on a 14-days-on/7-days-off schedule until progression/toxicity. Closed cohorts previously randomized patients with progressed leiomyosarcoma or synovial sarcoma to anlotinib versus dacarbazine (with crossover to anlotinib at progression) or anlotinib versus placebo in leiomyosarcoma.

ClinicalTrials.gov ID: NCT03016819

A Feasibility Study of Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma and Merkel Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable/recurrent/metastatic cutaneous squamous cell carcinoma or Merkel cell carcinoma (mixed histology allowed) that has progressed after prior anti–PD-1/PD-L1 therapy (or recurred within 6 months of perioperative ICI) and who have a resectable lesion for TIL harvest. Patients receive tumor harvest for autologous ex vivo expanded TIL therapy lifileucel (LN-145; reinfusion of tumor-reactive T cells) after cyclophosphamide/fludarabine lymphodepletion, followed by high-dose IL-2 (aldesleukin) support.

ClinicalTrials.gov ID: NCT07288073

A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial compares the combination of pembrolizumab and valemetostat tosylate, a dual EZH1/2 inhibitor, with pembrolizumab alone in patients with advanced or metastatic non-small cell lung cancer expressing PD-L1 ≥50% and lacking actionable genomic alterations. It includes patients who have not received prior systemic therapy and have a performance status of 0 or 1.

ClinicalTrials.gov ID: NCT06644768

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with recurrent metastatic breast cancer of any subtype who have progressed after all standard therapies, including those with stable brain metastases, to receive an HLA-matched, off-the-shelf allogeneic cellular immunotherapy (Bria-OTS, designed to induce anti-tumor immune responses), given alone or in combination with cyclophosphamide, peginterferon alpha-2a, and the PD-1 inhibitor tislelizumab.

ClinicalTrials.gov ID: NCT06471673

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls patients with unresectable or metastatic melanoma (including those previously treated with PD-1 inhibitors or BRAF-targeted therapies), advanced head and neck squamous cell carcinoma, or locally advanced/metastatic non-small cell lung cancer, providing treatment with autologous tumor-infiltrating lymphocyte (TIL) products—lifileucel (LN-144/LN-145) or next-generation PD-1-selected LN-145-S1—either as monotherapy or in combination with immune checkpoint inhibitors (ICIs). Eligibility requires at least one resectable lesion and ECOG 0-1, and excludes active autoimmune disease or untreated symptomatic brain metastases.

ClinicalTrials.gov ID: NCT03645928

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic, EGFR/ALK/ROS1-negative NSCLC who have progressed after prior immune checkpoint inhibitor and platinum chemotherapy, and who have a resectable tumor lesion and good performance status. Patients receive LN-145, an autologous tumor-infiltrating lymphocyte (TIL) therapy that reinfuses expanded tumor-reactive T cells following lymphodepleting chemotherapy, aiming to stimulate anti-tumor immunity.

ClinicalTrials.gov ID: NCT04614103